In today’s briefing:
- China Healthcare Weekly (Dec.31)-New Medical Device Policy, AstraZeneca to Acquire Gracell, PD-1+ADC
- Cardinal Health: The Powerhouse Behind Today’s Medical and Pharmaceutical Breakthroughs! – Major Drivers
- The Cigna Group: Enhancing Their Virtual Care With The Acquisition Of Bright.md Technology Platform! – Major Drivers
- Eli Lilly and Company: Expansion of Oncology Capabilities & Other Major Drivers
- Gilead Sciences Inc.: 3 Major Drivers That Can Propel This Pharma Giant Forward! – Financial Forecasts
- Illumina Inc: The Inside Story of Steady Revenues and Strategic Expansions! – Major Drivers
- Insulet Corporation: Revolutionizing Diabetes Care with Omnipod 5! – Major Drivers
- Medtronic PLC: Can The New FDA Approval Help Them Revolutionize Hypertension Treatment? – Major Drivers
- Mettler-Toledo International Inc.: Major Drivers
- Novo Nordisk A/S: Strategic Acquisition Of Embark Laboratories Fueling Their Growth in Obesity and Cardiometabolic Diseases! – Major Drivers
China Healthcare Weekly (Dec.31)-New Medical Device Policy, AstraZeneca to Acquire Gracell, PD-1+ADC
- Ministry of Finance and National Health Commission issued new policy strictly prohibiting public hospitals from borrowing to purchase medical equipment, which will change the investment logic of medical device sector.
- “PD-1+ADC” is expected to replace “PD-1+chemotherapy” as the first-line standard therapy. This will be a huge market. So, good story of ADC CDMO (such as WuXi XDC) would continue.
- The inspiration that AstraZeneca’s acquisition of Gracell brings to investors is IPO isn’t the only way for exit.Being acquired is also good, which will become more important in the future.
Cardinal Health: The Powerhouse Behind Today’s Medical and Pharmaceutical Breakthroughs! – Major Drivers
- Cardinal Health delivered a solid result and managed an all-around beat in the last quarter, exceeding expectations and achieving significant milestones.
- Consolidated enterprise results showcased a 10% increase in total revenue to $54.8 billion, primarily fueled by the Pharma segment.
- Despite flat revenue of $3.8 billion in the Medical segment, the company exceeded expectations in Q1.
The Cigna Group: Enhancing Their Virtual Care With The Acquisition Of Bright.md Technology Platform! – Major Drivers
- The Cigna Group surpassed Wall Street’s revenue and earnings expectations, maintaining the momentum for a sustained year in 2023.
- The company’s health services and benefits platforms continue to demonstrate strength, aligning with its mission to grow and serve effectively.
- They reported a total revenue of $49 billion and adjusted earnings per share of $6.77.
Eli Lilly and Company: Expansion of Oncology Capabilities & Other Major Drivers
- Eli Lilly and Company delivered a positive result and managed an all-around beat in the last quarter.
- The company reported a notable 37% increase in revenue compared to the same period in 2022.
- Research and development expenses saw a 34% increase, primarily due to higher development expenses for late-stage assets and increased investments in early-stage research.
Gilead Sciences Inc.: 3 Major Drivers That Can Propel This Pharma Giant Forward! – Financial Forecasts
- Gilead Sciences, Inc. delivered an all-around beat in the previous quarter, showcasing a 5% increase in the base business compared to the same period in 2022.
- Biktarvy achieved a remarkable 12% growth from the corresponding quarter in 2022.
- The increasing adoption of Trodelvy, a TROP-2-directed ADC, and cutting-edge cell therapies further fueled this upward trajectory.
Illumina Inc: The Inside Story of Steady Revenues and Strategic Expansions! – Major Drivers
- Illumina delivered mixed results for the previous quarter, with revenues below the analyst consensus.
- Despite lower revenue, non-GAAP net income surpassed expectations at $52 million or $0.33 per diluted share.
- While Core Illumina sequencing consumables revenue dropped 4% year-over-year, clinical sequencing consumables experienced a 10% growth, mitigating the decline.
Insulet Corporation: Revolutionizing Diabetes Care with Omnipod 5! – Major Drivers
- Insulet Corporation managed to exceed analyst expectations in terms of revenue as well as earnings.
- During the quarter, their revenue surpassed expectations, driven by the exceptional success of Omnipod 5, the revolutionary automated insulin delivery system.
- Omnipod 5’s impact was evident in accelerated new customer starts, with a remarkable 45% year-over-year revenue growth in the UK.
Medtronic PLC: Can The New FDA Approval Help Them Revolutionize Hypertension Treatment? – Major Drivers
- Medtronic plc delivered an all-around beat in the previous quarter, delivering mid-single-digit revenue growth across diverse business segments and global regions.
- Cardiovascular, Neuroscience, and Medical Surgical sectors all contributed to this growth, with Diabetes witnessing an acceleration to high single-digit growth.
- Synergistic businesses, encompassing Aortic, Coronary, Cardiac Surgery, and Endoscopy, achieved mid-single-digit growth, with standout performances in various segments.
Mettler-Toledo International Inc.: Major Drivers
- Mettler-Toledo International delivered a mixed set of results in its most recent result, with revenues falling short of Wall Street expectations but above-par earnings.
- In the third quarter, they reported sales of $942.5 million, indicating a 5% decline in local currency, while US dollar-based sales dropped by 4%, with currency effects contributing a 1% increase.
- In the Industrial business, sales declined 6% in the quarter due to weak core industrial product sales, particularly in China and the Americas.
Novo Nordisk A/S: Strategic Acquisition Of Embark Laboratories Fueling Their Growth in Obesity and Cardiometabolic Diseases! – Major Drivers
- Novo Nordisk A/S delivered a strong result and managed an all-around beat in the last quarter, boasting over 30% organic growth in both the top and bottom lines.
- The quarter witnessed an impressive milestone, with the company reaching 40 million people affected by diabetes.
- Financially, the company achieved a remarkable 33% sales growth and a 37% increase in operating profit at constant exchange rates.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
